CX-801, Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in Tumors

Alexey Berezhnoy, Ph.D., Presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), November, 8th, 2022.